StreetAlpha.app
Home › Stocks › SVRA

Savara Inc (SVRA)

Healthcare
$4.26
▼ −18.23%
LAST CLOSE · NOV 20

Savara is a biopharmaceutical company developing MOLBREEVI, an inhaled investigational drug for a rare lung disease. It last closed at $4.26 on Nov 20, down 18.23% on the day. For the quarter ended Sep 2026, SVRA reported EPS of -$0.17. Over the last 12 months SVRA insiders bought $0 of stock on the open market and sold $2.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is SVRA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold SVRA.

Key Stats

Last 12 months
Results
Net income
−$152.7M
EPS (diluted)
−$0.60
Free cash flow
−$130.9M
Valuation
Market cap
$939.9M
220.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$29.8M
At Sep 30
Debt
$30.2M
At Sep 30
Shareholder equity
$107.8M
Shares outstanding
220.6M
At Nov 9
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$43.0M−$43.0MFY2021FY2022: −$38.1M−$38.1MFY2022FY2023: −$54.7M−$54.7MFY2023FY2024: −$95.9M−$95.9MFY2024FY2025: −$118.8M−$118.8MFY2025

From SVRA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Next report
—
No date on file yet
Reported EPS
-$0.17
Quarter ended Sep 2026
Year ago EPS
-$0.14
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.13Dec '24Mar 2025: -$0.12Mar '25Jun 2025: -$0.14Jun '25Sep 2025: -$0.14Sep '25Dec 2025: -$0.13Dec '25Mar 2026: -$0.15Mar '26Jun 2026: -$0.16Jun '26Sep 2026: -$0.17Sep '26Latest -$0.17
Revenue by quarter
Not enough quarters on file yet.
StreetAlpha's call on SVRAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on SVRA: 0 upgrades, 0 downgrades, 0 initiations · Targets mentioned $9.00
HC WainwrightTarget cut
Nov 21 $9.00

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on SVRA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on SVRA

Technical Analysis

SVRA · as of the Nov 20 close · updated each morning
Downtrend

The stock is 11% below its 20 day and 14% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the swing low (Oct 23) at $4.13, and the nearest resistance the Pivot R1 at $4.52.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 9.2%/day
Key levels
$7.0052 week high+64.3%
$5.31200 day average+24.6%
$5.23100 day average+22.8%
$4.99Swing high (Oct 20)+17.1%
$4.8650 day average+14.1%
$4.7520 day average+11.5%
$4.52Pivot R1+6.1%
$4.26Pivot+0.0%
$4.26Last close
$4.13Swing low (Oct 23)−3.1%
$4.0052 week low−6.1%
$4.00Pivot S1−6.1%
Indicators
RSI (14)41.95Middle of its rangeNeutral
MACD-0.05Below its signal lineBearish
Stochastic50.5Middle of its rangeNeutral
ADX (14)14.1No clear trend
Williams %R-80.6Oversold below −80, overbought above −20Oversold
CCI (20)-182.3Oversold below −100, overbought above 100Oversold
Rate of change−11.8%Change over 10 sessionsBearish
ATR (14)$0.39Typical daily range, 9.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for SVRA

What happened before

See how SVRA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow SVRA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How SVRA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for SVRAHow many large options trades hit SVRA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

SVRA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲102 buying vs 70 selling
  • ●Held by funds -0.0 pts
  • ●Funds holding +1
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding183182+0.5%
In funds' top 10660.0%
Held by funds101.5%101.6%−0.0 pts
New / increased26 / 7622 / 70+10.9%
Reduced / sold out45 / 2557 / 26−15.7%
Put/call ratio0.12––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SVRA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

SVRA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.4M2 sales · 2 insiders
2025-12 sold $121K2026-06 sold $2.2MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 22David L LowranceCFOSale394,528$5.68$2.2M
Dec 19, 2025David A RamsayDirectorSale20,000$6.06$121K
Jun 20, 2025Richard J HawkinsDirectorBuy48,225$2.04$98K
May 29, 2025Joseph S McCrackenDirectorBuy10,000$2.08$21K
Mar 31, 2025David A RamsayDirectorBuy150,000$2.78$417K
Dec 16, 2024Richard J HawkinsDirectorSale8,000$3.32$27K
Every insider buy and sale for SVRA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See SVRA insider trades →

From SEC Form 4 filings by SVRA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SVRA is in one of them and how their past SVRA trades turned out.

SVRA in the AI portfolios
Loading…

SVRA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SVRA in an article yet. Here's the latest on the wider market.

SVRA in the news

About Savara

Savara is a biopharmaceutical company that develops treatments for rare respiratory diseases. Its main product candidate, MOLBREEVI, is an investigational inhaled drug for patients with autoimmune pulmonary alveolar proteinosis, a rare lung disease in which a substance called surfactant builds up in the air sacs of the lungs. The drug is given through a nebulizer device and is not yet approved for sale. The company is based in Austin, Texas.

Headquarters
Austin, TX